Labcorp reported fourth quarter 2025 revenue of $3.52 billion, which missed Wall Street estimates. However, the company exceeded earnings expectations, reporting adjusted earnings per share of $4.07 against a consensus of $3.95. Full year 2025 revenue reached $13.95 billion and adjusted EPS was $16.44. For fiscal 2026, Labcorp provided guidance for adjusted earnings between $17.55 and $18.25 per share on revenue between $14.61 billion and $14.79 billion, with midpoint growth of 8.9% for adjusted EPS. The company signed or closed 13 partnership transactions, launched over 130 new tests, and announced a strategic investment in a new 500,000 square foot Central Laboratory facility. The stock declined despite the earnings beat, with the revenue miss appearing to be the primary driver of the selloff.
Read full analysisLabcorp reported fourth quarter 2025 revenue of $3.52 billion, which missed Wall Street estimates. However, the company exceeded earnings expectations, reporting adjusted earnings per share of $4.07 against a consensus of $3.95. Full year 2025 revenue reached $13.95 billion and adjusted EPS was $16.44. For fiscal 2026, Labcorp provided guidance for adjusted earnings between $17.55 and $18.25 per share on revenue between $14.61 billion and $14.79 billion, with midpoint growth of 8.9% for adjusted EPS. The company signed or closed 13 partnership transactions, launched over 130 new tests, and announced a strategic investment in a new 500,000 square foot Central Laboratory facility. The stock declined despite the earnings beat, with the revenue miss appearing to be the primary driver of the selloff.
Labcorp is one of the two largest clinical laboratory companies in the U.S., providing diagnostic testing, drug development services, and specialty testing across oncology, neurology, and other fields. The company recently launched the first FDA-cleared Alzheimer's blood test for primary care. Today's selloff was driven by a Q4 revenue miss that overshadowed an earnings beat and slightly above-consensus 2026 guidance.